Business
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones,
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally activated IFN⍺2b cytokine For U.S. media and investors onlyDUBLIN, March 18, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company and its partners will present one oral and six poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego.The research highlights meaningful progress across Jazz's oncology portfolio, including new findings from company-sponsored research evaluating Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody; JZP898, an investigational, differentiated, conditionally activated interferon alpha-2b (IFN⍺2b) cytokine pro-drug designed for activation within the tumor microenvironment; and imipridone compounds including Modeyso™ (dordaviprone), a protease activator of the mitochondrial caseinolytic protease P (ClpP) and a dopamine D2 receptor (DRD2) inhibitor.\"Jazz is presenting research at AACR that highlights how we are advancing our oncology portfolio with pace and rigor to deliver differentiated science and new insights across multiple development programs,\" said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. \"Zanidatamab is already delivering meaningful benefits for adult patients with previously treated, unresectable or metastatic HER2+ (IHC 3+) biliary tract cancer. We are advancing our program in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma, and generating a robust body of evidence that characterizes its distinct HER2 biology and its potential across additional HER2-expressing tumors, including HER2+ breast cancer. The NeoZanHER trial data being presented at AACR provide supporting evidence for our ongoing research in early-stage breast cancer.\"Highlights at the AACR Annual Meeting include:An oral presentation with results from the Phase 2 single-arm, open-label NeoZanHER trial (NCT05035836) evaluating zanidatamab for the investigational use as neoadjuvant monotherapy in patients with early-stage HER2+ breast cancer. At six weeks, za...